Biotech Patent Lawyer Howard Suh Joins Fox in New York

October 15, 2019 – Press Releases

Fox Rothschild LLP welcomes Howard S. Suh in New York as a partner in the Intellectual Property Department.

“Howard has a superb reputation in the biotechnology and pharmaceutical sectors for providing strategic guidance on patents and litigation,” said Janet M. MacLeod, Ph.D., the managing partner of Fox’s New York office and former head of the firm’s Patents Practice Group. “We are thrilled to have him on our team.”

Suh has led some of the largest patent cases in the pharmaceuticals and biotechnology sectors. A seasoned intellectual property litigator, he coordinates appellate litigation before the Federal Circuit and the U.S. Supreme Court, and his patent litigation representations extend to a variety of other fields, from medical devices to materials science.

Notably, Suh has handled patents related to cutting-edge biopharmaceuticals, including recombinant-produced insulin, human growth hormone (HGH), tissue plasminogen activator (t-PA), erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF) and chimeric antibodies, as well as agricultural biotechnology, having represented multinational crop-sciences companies in patent litigation involving genetically modified corn and soybean seeds.

Suh is also experienced in litigating patent claims involving small-molecule drugs, including cough-and-cold products, oncology drugs and immunology treatments. He also assists pharmaceutical clients in corporate transactions and acquisitions, performing due diligence of patent portfolios, evaluating threats from competitive patents and preparing agreements.

Previously a partner at Holland & Knight, Suh earned his J.D. from New York University and his B.A. from Columbia University.